AKT1 and breast carcinoma: We analyzed the relationships between drug IC50 and DMAP1 expression in breast cancer cell lines and found that higher DMAP1 expression had a higher IC50 for some PI3K/Akt signaling pathway inhibitors such as MK-2206.